Systemic Aspergillosis and Systemic Candidiasis Market Size, Trends and Growth Analysis by 2027

The global market for systemic aspergillosis and systemic candidiasis is projected to grow significantly, reaching approximately US$ 8,247.5 million by 2027, up from US$ 6,056.3 million in 2019. This growth represents a compound annual growth rate (CAGR) of 4.0% from 2020 to 2027.

Several factors are contributing to this market expansion, notably the rising prevalence of fungal infections and the increasing incidence of hospital-acquired fungal infections. However, challenges such as the growing resistance to antifungal medications and the potential side effects associated with these drugs may hinder market growth during the forecast period.

One of the most concerning fungi in this context is Candida Auris, which poses a significant global health risk. This pathogen can lead to severe illnesses among hospitalized patients across various countries, including the United States. Patients infected with C. Auris can remain colonized for extended periods, and the fungus can survive on surfaces within healthcare settings, facilitating its transmission between patients. A report from the CDC in 2021 highlighted that cases of C. Auris have been identified in patients with recent healthcare exposure in countries such as Egypt, India, Kenya, Kuwait, Pakistan, South Africa, South Korea, the UAE, and Venezuela, indicating its potential as a hospital-acquired infection.

The emergence of C. Auris is recognized as a critical issue related to nosocomial transmission and infection control within hospitals. As of January 31, 2019, the CDC reported 560 cases of C. Auris infections in the United States. Despite implementing measures to curb fungal infections in intensive care units (ICUs), new cases continue to arise, suggesting a trend towards endemicity. This persistence underscores the ability of C. Auris to maintain infections in clinical environments, thereby facilitating its spread in critical care settings. Unlike other species of Candida, C. Auris can colonize various anatomical sites, including the skin, axilla, rectum, and stool, and can contaminate hospital equipment and surfaces, perpetuating a cycle of infection and transmission, particularly in ICUs.

Furthermore, a report from the NCBI published in January 2020 indicated that increased travel to countries with high rates of C. Auris transmission, along with a higher influx of migrants, contributes to the rapid spread of this fungus. Public hospitals have reported a higher prevalence of C. Auris compared to private facilities, likely due to overcrowding and inadequate infection control practices. Preliminary data from the Post Graduate Institute of Medical Education and Research in Chandigarh revealed that approximately 7 out of every 1,000 patients admitted to ICUs in India are affected by fungal infections. This data was gathered from 27 hospital ICUs across the nation, comprising 11 government and 16 private hospitals. Consequently, the rising incidence of hospital-acquired fungal infections is driving the demand for effective treatments to prevent systemic aspergillosis and systemic candidiasis, thereby fostering market growth.

The global market for systemic aspergillosis and systemic candidiasis is categorized by type and application. In terms of type, the market includes segments such as voriconazole, liposomal amphotericin B, systemic oral azoles, topical antifungal agents, and others. In 2019, the systemic oral azoles segment commanded the largest market share and is anticipated to experience the fastest growth during the forecast period, driven by the increasing number of invasive fungal infections.

Regarding application, the market is divided into chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and others. The ABPA segment held the largest share in 2019 and is expected to grow at the highest rate in the coming years.

Key secondary sources utilized in the preparation of this report include the Post Graduate Institute of Medical Education and Research, the International Society for Human and Animal Mycology, the Food and Drug Administration, and the World Health Organization.